Abstract
Since the success of hGH synthesis by recombinant DNA technology (Goeddel et al., 1979) , several investigators have reported the properties and biological activities of methyonyl-hGH (met-hGH) in man and animals (Olson et al., 1981 , Hizuka et al., 1982 , Rosenfeld et al., 1982a , 1982b , Frigeri et al., 1982 , Hintz et al., 1982 . We have previously reported biological effects of methGH similar to those of pituitary human growth hormone in eight healthy male volunteers (Takano et al., 1983) . In this 
Discussion
We investigated the effect of methionyl hGH on growth in patients with pituitary dwarfism and observed excellent growth response in all patients.
Their height increased between 1.5 and 2.7cm during 3 months of treatment, which corresponded to between 6 and 10.8cm per year. There are huge amounts of records on the treatment of pituitary dwarfism with pituitary-hGH. About fifteen hundred patients with growth hormone deficiency have been treated with pituitary growth hormone in Japan and there is a remarkable height increase of between 5 and 12 cm in the first year of treatment. The effect of met-hGH on growth was comparable to that of pituitary-hGH.
A remarkable difference between methGH and pituitary hGH was the antigenicity. There were many reports on the antigenicity of pituitary-hGH (Underwood et al., 1974 , Fraiser et al., 1974 , Kaplan et al., 1974 . They reported that about 40% of the patients developed detectable antibodies during the treatment period. Kaplan et al., (1974) reported that 38 out of 98 patients treated with GH by Drs. Wilhelmi, Raben and/or Saxena had anti-hGH antibodies and that antibodies were detectable by 3 months after the onset of therapy in 3, by 6 months in 9, and thereafter in the rest of the patients. The main cause of the antigenicity was the polymeric hGH produced during the purification processes. After the improvement of purification and use of frozen pituitary gland, pituitary-hGH became less antigenic. During treatment with KABI's hGH (Crescormone(R)), only one out of twenty patients developed antibodies to hGH in serum (Hall and Olin 1972) . Shizume et al. (1974) also reported that Crescormone (KABI-hGH) was less antigenic. We detected antibodies in only four out of 48 patients treated with pituitary hGH for more than six months. Even when antibodies were produced, their titers were low and did not interfere with the effect of hGH in any of the cases. After treatment with met-hGH, antibodies were produced in all patients after 2 months. In spite of the formation of anti-hGH antibody, growth rate increased between the 2 nd and 3 rd month of treatment in 4 cases (Nos. 1, 3, 5 and 7), it decreased in 3 cases (Nos. 2, 8 and 10) and did not change in 3 cases (Nos. 4, 6 and 9). High titers of anti-hGH antibody might attenuate the growth effects of hGH. However, more long-term treatment will be required to examine this possiblility. There were no denatured forms of hGH in these preparations (personal communication from Kabi); however very minute amounts of E. coli protein were presented. This antigenicity might be due to a conjugated form of met-hGH with this protein. Thus, a more purified hGH might produce antibodies much less frequently. The possibility that the methionine residue could be responsible for the production of antibodies is not completely denied at present.
